BiotechTube
Photys Therapeutics

Photys Therapeutics

Cambridge, United States· Est.
photys.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Photys Therapeutics is a private, preclinical-stage biotech founded in 2021, based on pioneering bifunctional chemistry from the Broad Institute. The company has developed a versatile platform of proximity-inducing chimeric molecules (PROTACs, tPRIME, PHICS) designed to degrade, transcriptionally regulate, or phosphorylate target proteins with high precision. Backed by a $75M Series A and strategic collaborations with Novo Nordisk and Polymed, Photys is advancing a pipeline aimed at historically challenging targets in oncology, immunology, and cardiometabolic disorders.

OncologyAutoimmune and Inflammatory DiseasesCardiometabolic Diseases

Technology Platform

Proprietary suite of bifunctional, proximity-inducing platforms: PROTAC for protein degradation, tPRIME for transcriptional regulation, and PHICS for precise, induced phosphorylation.

Funding History

1
Total raised:$75M
Venture$75M

Opportunities

The company's PHICS platform represents a first-in-class approach to controllably phosphorylate target proteins, opening the 'undruggable' proteome and creating potential new therapies for diseases driven by dysfunctional signaling.
Strategic partnerships with industry leaders like Novo Nordisk provide validation, funding, and development expertise in large therapeutic markets.

Risk Factors

The novel and complex nature of its bifunctional molecules, particularly the unproven PHICS platform, carries significant translational risk from preclinical models to human safety and efficacy.
The company operates in a highly competitive landscape with numerous well-funded players focused on protein degradation and proximity-based therapeutics.

Competitive Landscape

Photys competes in the rapidly growing field of proximity-based therapeutics, facing established public companies like Arvinas, Kymera Therapeutics, and Nurix Therapeutics in protein degradation. Its differentiation lies in its multi-platform approach, especially the novel PHICS technology for induced phosphorylation, which is less crowded than the PROTAC space.

More companies in Small Molecule Drugs →More companies in United States →